Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Nearly four months after issuing a voluntary recall of all lots of unexpired sterile drug products, Cantrell Drug Company has filed for bankruptcy.
The PE firm made the investment just three years ago.
A little more than two years after acquiring Sprout, Valeant is selling off the developer of the female sex drive drug Addyi.
Tonghua Golden-Horse Pharma and Golden Meditech Holdings -- will submit bids in the second round of an auction to acquire I-MED Radiology.
Moderna CEO said the company was not likely to float its initial public offering until the company has solid data on its lead mRNA treatment.
The acquisition is expected to close by the end of 2017.
Neurocrine’s third-quarter financial results didn’t just impress, they blew everybody away.
Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.